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Key points:  
PET-CT is the modern standard for staging Hodgkin Lymphoma and can replace contrast 
enhanced CT in the vast majority of cases. 
Agreement between expert and local readers is sufficient for the Deauville criteria to assess 
response in clinical trials and the community. 
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Abstract  
International guidelines recommend PET-CT should replace CT in Hodgkin Lymphoma (HL). 
The aims of this study were to i) compare PET-CT with CT for staging and ii) measure 
agreement between expert and local readers, using a five-point scale (Deauville criteria), to 
adapt treatment in a clinical trial  ‘Response Adapted Therapy in Advanced Hodgkin 
Lymphoma’ (RATHL) www.cancer.gov/clinicaltrials, reference NCT00678327. Patients were 
staged for the trial using clinical assessment, CT and bone marrow biopsy (RATHL stage).  
PET-CT was performed at baseline (PET0) and after 2 chemotherapy cycles (PET2) in a 
response-adapted design.  PET-CT was reported centrally by experts at 5 national core labs.  
Local readers optionally scored PET2 scans. The RATHL and PET-CT stages were compared.  
Agreement amongst experts and between expert and local readers was measured. RATHL 
and PET0 stage were concordant in 938 (80%) patients.  PET-CT upstaged 159 (14%) and 
downstaged 74 (6%) patients. Upstaging by extranodal disease in bone marrow (92), lung 
(11) or multiple sites (12) on PET-CT accounted for most discrepancies.  Follow-up of 
discrepant findings confirmed the PET characterisation of lesions in the vast majority.  Five 
patients were upstaged by marrow biopsy; 7 by contrast-enhanced CT in bowel and/or liver 
or spleen. PET2 agreement amongst experts (140 scans) with kappa (95% CI) of 0.84 (0.76 – 
0.91) was very good and between experts and local readers (300 scans) at 0.77 (0.68-0.86) 
was good. These results confirm PET-CT as the modern standard for staging HL and that 
response assessment using Deauville criteria is robust enabling translation of RATHL results 
into clinical practice. 
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Introduction 
Positron Emission Tomography (PET) and PET-CT, using 2-deoxy-2-[fluorine-18]fluoro-D-
glucose (FDG),  has been extensively used for imaging patients with Hodgkin Lymphoma (HL) 
1-5
 . International guidelines recently recommended that PET-CT be used for routine staging 
of FDG-avid lymphomas and for response assessment using a five-point scale (5-PS), the so-
called ‘Deauville criteria’ 
6,7
.   
PET-CT was preferred for staging due to improved accuracy compared with CT and as a 
baseline for subsequent response assessment 
6
.  Contrast enhanced CT (ceCT) may be 
required if accurate nodal measurement is needed e.g. in clinical trials, assessment of bowel 
involvement,  compression/thrombosis of central vessels and for radiation planning
7
.  Direct 
comparison between ceCT and PET-CT when the CT component is performed as a low-dose 
unenhanced scan, suggests that higher dose ceCT has no impact on lymphoma management 
8,9
. Further, changes in FDG uptake are more relevant than changes in nodal size for 
response assessment 
6
.  Despite this, both ceCT and PET-CT are frequently performed at 
diagnosis, with added cost and radiation exposure.   
PET is reported to alter stage compared with CT 
3,10
, but most publications are retrospective 
and used stand-alone PET 
11-16
. Previous publications compared imaging techniques but do 
not report the impact of imaging on the more relevant final clinical stage, inclusive of bone 
marrow biopsy and some publications included patients with HL and non-Hodgkin 
lymphoma (NHL) 
17-21
.   
Response assessment with the 5-PS has been reported by a number of investigators to have 
good interobserver agreement in a training set of 50 patients 
22
, in a study of 260 advanced 
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HL patients with international expert readers 
23
 and in paediatric HL
24
. The 5-PS also 
improves the positive predictive value of PET compared with previous International 
Harmonisation Criteria 
25
. These studies, however, were all retrospective and the 5-PS was 
not used to direct therapy.   
The aims of this study were to determine in a large cohort of patients with advanced HL, 
within a prospectively acquired clinical trial: 
1. the difference in staging when unenhanced PET-CT is used in place of standard 
assessment with clinical examination, ceCT, and bone marrow biopsy and,  
2. the agreement amongst experts and between local readers using the 5-PS to adapt 
treatment in ‘real time’. 
Methods 
Patients were registered in the ‘Response Adapted Therapy in Advanced Hodgkin 
Lymphoma’ (RATHL) study (www.cancer.gov/clinicaltrials, reference NCT00678327) and 
gave written informed consent in accordance with the Declaration of Helsinki. The study had 
Human Ethics Committee approval in all participating countries.  
i) Staging   
Patients underwent clinical assessment, ceCT of neck, thorax, abdomen, pelvis and bone 
marrow biopsy to assess stage. RATHL included patients with stages IIB-IV and stage IIA with 
adverse features. Patients also underwent a PET-CT scan with low-dose unenhanced CT at 
staging (PET0).  ceCT and PET-CT scans were performed within 28 days of enrolment. PET-CT 
scans were acquired around 60 minutes after the intravenous injection of 350-550MBq FDG. 
The ceCT scans at diagnosis were reported by the radiologist at the recruiting centre and 
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clinical assessment, CT findings and bone marrow biopsy were used to assign the final 
RATHL stage by the treating clinician on the case report form (CRF). In individual cases, 
ultrasound or MRI were also used for staging. Inclusion in the study was based on the RATHL 
stage not PET-CT. The PET-CT stage was assigned by central readers at core labs in UK, Italy, 
Sweden, Denmark and Australia without knowledge of RATHL stage, marrow biopsy or 
patient outcome. Causes for discrepancy in stage between PET-CT and other modalities 
were assessed with reference to the imaging reports, bone marrow biopsy results and by 
observing the changes that occurred with treatment on PET scans performed during 
chemotherapy. ceCT scans were not re-reviewed centrally.  PET-CT scans were performed at 
multiple international centres using standardised methods for acquisition and quality 
control
26
. 
ii) Response assessment 
PET-CT was repeated after two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine 
(ABVD) chemotherapy (PET2).  All scans were PET-CT and stand-alone PET scans were not 
permitted in the trial.  PET2 scans were performed 9-13 days after day 15 of cycle 2. 
PET2 was scored using the 5-PS 
6
, according to the level of the most intense residual FDG 
uptake at involved sites on PET0 as follows: 
1. no uptake  
2. uptake ≤ mediastinum  
3. uptake > mediastinum but ≤ liver  
4. uptake moderately higher than liver 
5. uptake markedly higher than liver and/or new lesions 
X     new areas of uptake unlikely to be related to lymphoma 
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Scores 1, 2, 3 were regarded as ‘negative’ and scores 4, 5 as ‘positive’.  Score 5 was regarded 
as uptake > 3 times the maximum SUV in normal liver. 
Patients with negative PET2 were randomised to continue with four cycles of ABVD or have 
de-escalation of treatment with four cycles of AVD.  Patients with positive PET2 had 
escalated treatment with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine, prednisone (BEACOPP)-escalated or BEACOPP-14, according to the treating 
centre preference. A third PET-CT (PET3) was performed 9-13 days after day 8 of cycle 3 of 
BEACOPP-escalated or 2-6 days after day 8 of cycle 4 of BEACOPP-14 to ensure effectiveness 
of therapy. It was left to the treating physician’s discretion whether patients were offered 
salvage therapy if PET3 remained positive.  An end-of treatment PET scan was not 
mandated.  Patients with a negative PET2 or PET3 scan were not recommended to receive 
consolidation radiotherapy as routine, although local investigators had discretion to use 
radiotherapy if they felt it necessary.   
 
 
PET2 was scored at the core labs within 72 hours and this score was used to direct 
treatment.  To assess the level of agreement, readers from all core labs read the same 
paired PET0 and PET2 scans from: 1) a training set of 50 patients 
22
 2) the first 10 patients 
scored at each core lab and 3) a further 10 patients scored at each core lab during the trial. 
Readers at ‘local’ PET Centres were given the option to score scans.  Levels of agreement 
were measured between central (core lab) readers and between local and central readers, 
using non-weighted kappa statistics
27
 [Stata version 12.1; Stata Corp, Texas].  Using this 
threshold, uptake in lesions higher than normal liver uptake resulted in treatment 
escalation.  Agreement was also measured regarding score 1,2 as negative and score 3,4,5 
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as positive, as this threshold has been used as a benchmark for de-escalation in trials 
involving patients with HL 
1,28,29
. 
Kappa values between 0.81-1.00 indicate very good agreement, 0.61-0.80 good agreement, 
0.41 -0.60 moderate agreement, 0.21- 0.4 fair agreement
30
.   
Results 
i) Staging 
1214 patients were registered from 2008 - 2012.  1171 baseline PET-CT scans were available 
for staging assessment which was performed retrospectively (Figure 1).  
There was agreement between the RATHL stage and the PET-CT stage in 938 (80%) patients.  
159 patients (14%) were upstaged and 74 patients (6%) were downstaged by PET-CT (Table 
1).  The main reason for upstaging was detection of extranodal disease (Table 2), most 
commonly in bone marrow (Figure 2).  Upstaging due to nodal involvement also occurred, 
mostly below the diaphragm (Table 2).  Reasons for downstaging included enlarged nodes 
and/or spleen which were not FDG-avid and extranodal sites with abnormal morphology but 
no FDG uptake (Table 2).   
The PET2 scans of patients with discrepant staging findings were compared with the PET0 
scan (Supplementary Table 1). At PET2, FDG uptake at sites that resulted in upstaging, 
decreased in parallel with other sites of disease during treatment in all cases (Table 2). 
Twenty patients had extranodal lesions on CT that were not FDG-avid.  Five of these twenty 
patients had lesions that did not change on treatment (Figure 3) and were considered 
unlikely to represent lymphoma (1 adrenal adenoma, 3 lung nodule/s, 1 bone lesion). One 
patient had a 37mm cavitating lung nodule on CT, which enlarged from 5mm seven days 
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prior on PET-CT, and was probably inflammatory. Six patients had indeterminate lung 
nodules and one patient had lobar consolidation that all resolved; 3 patients had pleural 
effusions that resolved – in all these cases the changes may have been reactive, 
inflammatory or related to lymphoma.  There were four patients - small bowel (1), liver 
lesions (2) and 1 patient with bowel and liver lesions - where ceCT was considered more 
likely to indicate the correct stage.  Three patients had splenic lesions on ceCT not seen on 
PET.  Bone marrow involvement was missed on PET-CT but identified on biopsy in five 
patients.   
There were 21 cases where review of the reports suggested that the same imaging findings 
had been differently interpreted by the local radiologist and the core lab PET CT reader or 
the local radiologist and the treating clinician (Table 2). 
ii) Reporting of early response assessment 
1123 PET2 scans were assessable in the trial (Figure 1). 223 PET2 scans were performed in 
the PET Centre of one of the core labs (Figure 1).  Local readers scored 300 of the remaining  
900 scans (33%).   140 PET2 scans were scored by all readers at the five core labs.    
When the liver threshold was used, there was agreement between core labs that a scan was 
‘negative’ (score 1-3) or ‘positive’ (score 4 or 5) in 122/140 scans; Kappa (95% CI): 0.84 (0.76 
– 0.91) indicating very good agreement. There was agreement between central and local 
readers in 276/300 scans; Kappa (95% CI): 0.77 (0.68 – 0.86) (Table 3A) indicating good 
agreement. 
When the mediastinal threshold was used, there was agreement between core labs that a 
scan was ‘negative’ (score 1 or 2) or ‘positive’ (score 3-5) in 81/140 scans; Kappa (95% CI): 
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0.58 (0.50 – 0.66) indicating moderate agreement.  There was agreement between central 
and local readers in 249/305 scans, Kappa (95% CI): 0.64 (0.55 – 0.73) (Table 3B) indicating 
good agreement.   
Identical scores ranging from 1-5 were given in 169/300 PET2 scans by central and local 
readers (Table 3C).  When assigning scans as positive or negative,  15 PET2 scans scored by 
local readers as ‘positive’ were deemed ‘negative’ by central review whereas 9 PET2 scans 
scored by local readers as ‘negative’ were deemed ‘positive’ by central review using the liver 
threshold that determined treatment.   
161 PET3 scans were performed, 26 at the PET Centre of one of the core labs (Figure 1).  
Local readers scored 47 of the remaining PET3 scans (36%). Using the liver threshold, there 
was agreement amongst central and local readers that a scan was ‘negative’ or ‘positive’ in 
45/47 scans; Kappa (95% CI): 0.91 (0.78 – 1.00) indicating very good agreement. For the 
mediastinal threshold, there was agreement in 39/47 scans; Kappa (95% CI): 0.61 (0.45 – 
0.87) indicating good agreement.  
Identical scores ranging from 1-5 were given in 24/47 PET3 scans by central and local 
readers using the liver threshold.   
 
Discussion 
 
Our study is the first to compare PET-CT staging with the established standard of clinical 
assessment, contrast-enhanced CT and bone marrow biopsy stage in a large cohort of 
patients with advanced HL in an international trial.  PET-CT altered staging in 20% of 
patients compared with the standard approach, which is at variance with earlier reports that 
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suggested stage change occurred more often in patients with early stage rather than 
advanced disease 
10,20
.  Upstaging occurred more frequently than downstaging with 
extranodal disease accounting for 74% of the upstaged scans, mostly due to an increased 
sensitivity of PET for detecting bone marrow involvement.  
Baseline and response scans were compared and the findings were correlated with other 
imaging, where available, to determine the etiology of lesions that accounted for the 
discrepancy in stage.  This supported the notion that PET-CT stage is more accurate than CT 
in the majority of cases.  There were only 4 patients with organ involvement and 3 with 
probable splenic involvement identified on ceCT that were missed on PET-CT. Bone marrow 
biopsy identified involvement in 5 cases (0.4%) where there was a normal marrow 
appearance on PET-CT confirming that routine bone marrow biopsy is no longer required
7,31
.   
We cannot determine if staging by PET-CT impacted on management because patients were 
registered in the trial based on having at least stage IIA disease with adverse risk factors on 
other imaging and marrow biopsy. Upstaging by PET-CT would have been unlikely to impact 
management as patients had already been assessed as requiring full course chemotherapy.  
Similarly, downstaging from stage 4 to stage 3 would not have impacted on treatment. PET-
CT, however, downstaged 56 patients to stage 2 and 1 patient to stage 1 (5% of the study 
population) and this could potentially influence treatment choices.   
 
Our results are in keeping with earlier reports 
11,13-16
 that PET stages HL patients differently 
to ceCT in approximately 15 - 30% of cases. Early reports had fewer patients, were 
retrospective and published prior to the widespread introduction of PET-CT 
11-16
.  More 
recently Hutchings et al
3
 compared PET with CT staging prospectively in 99 patients with HL, 
(61 with PET-CT) and Rigacci in 186 patients ( 56 with PET-CT)
10
.  Upstaging, especially by 
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identification of extranodal sites, occurred more frequently than downstaging, similar to our 
findings. 
3
 Lesions were also overlooked on CT and more easily identified on PET 
3,10,20
.   
 
The ‘truth’ as to whether lesions identified only on PET represent lymphoma is difficult to 
determine as biopsy of discrepant lesions is rarely performed. Correlative imaging, 
treatment response, follow-up, biopsy, or a combination, usually serves as a reference 
standard 
3,10-14
. Young et al, in 49 HL patients, verified stage by laparotomy in 11 patients 
and biopsy of discordant lesions in the remainder 
32
. PET stage was correct in 26 upstaged 
patients and a single patient downstaged compared to CT.  Taken together, these studies 
demonstrated improved sensitivity and similar specificity using PET compared to CT.    
Changes in management were reported in 12/186 patients by Rigacci et al 
10
.  Ten patients 
were upstaged from limited to advanced disease and 2 patients had an increase in the 
radiotherapy field using PET.  Hutchings et al
3
, reported that 7 patients upstaged by PET to 
advanced disease were treated for limited disease but only 1 patient developed progressive 
lymphoma. Eighteen patients had disease progression overall, suggesting that understaging 
by CT probably did not adversely impact on outcome.  The same group later reported, 
however, that the routine use of PET-CT in their clinical practice resulted in stage migration, 
with a higher risk of progression associated with focal FDG-avid skeletal lesions 
33
. Bone 
marrow involvement was the most common reason for discrepancy in stage between PET 
and CT in our series.  Munker et al 
13
 also reported significantly more treatment failures 
among patients staged as I or II on CT yet III or IV on PET compared with patients who were 
stage I or II by both CT and PET.  More accurate delineation of disease is thus likely to be of 
benefit for patient management and for radiation planning 
10,15
 .   
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International guidelines have recommended that PET-CT should be used for staging of FDG-
avid lymphomas
7
, because it is more accurate than CT and because a staging scan improves 
the accuracy of response assessment
6
.  The role of ceCT in staging is still debated although 
the international guidelines concluded that ceCT had limited application
7
 as it rarely altered 
staging or management. 
8,9
 Our study confirms this conclusion; organ involvement was 
detected on ce-CT but not PET-CT in 4 patients and splenic lesions in 3 patients, leading to 
stage change.  On the other hand PET-CT detected extranodal disease in 118 patients and 
splenic FDG-avid foci in 7 patients and stage was changed.  Further the effective dose 
associated with ceCT is approximately 16mSv, which is similar to the combined dose from 
PET with lower dose unenhanced CT.  Avoiding  ceCT for staging would thus reduce a 
patient’s radiation dose by 50%.  Although ceCT may be required for planning radiotherapy, 
in our study, less than 10% of patients required this 
7
. 
PET-CT is recommended for response assessment in FDG-avid lymphomas using the 5-PS
34
.  
The 5-PS has good interobserver agreement
22,24,25,35-37
 and is predictive of patient 
outcomes
29,35,38-40
, especially in advanced HL
37,41
.   An advantage of the 5-PS is that the 
threshold used to define complete metabolic response can be altered according to the 
clinical context or research question
34
.  In the RATHL design where patients with a ‘positive’ 
scan received escalation from ABVD to BEACOPP, investigators preferred to use the liver 
threshold to avoid the risk of over-treating patients.  In some trials designed to explore de-
escalation strategies, a lower mediastinal threshold has been used to avoid the risk of 
under-treating patients
1,28,29
.  Yahalom  expressed concern that the good agreement 
reported amongst expert readers may not be reproducible in the community setting, in 
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particular, if treatment was adapted on the basis of the result
42
.  Our study demonstrated 
similar levels of agreement amongst experts and local readers, with good or very good 
agreement for the liver but lower moderate to good agreement for the mediastinal 
threshold.  In RATHL the outcome for patients with a ‘negative’ scan was not influenced by 
the PET2 score
43
 and our observations suggest that the liver is likely to be a more 
reproducible threshold, although readers may possibly have paid closer attention to the 
decision to assign a score of 4 rather than 3, knowing this would result in treatment 
escalation.  The better agreement using the liver 
43
 may be explained by the higher uptake 
in liver than mediastinum, so the contrast between lesions with low-grade uptake and the 
reference region is easier to appreciate 
22,23
. In addition, there is more uniform uptake in the 
liver than the mediastinum where uptake can be heterogeneous with focal uptake in the 
vessel wall.  Standardisation of patient preparation and scanning are important to ensure 
homogenous uptake in the liver 
44
.  The agreement for scoring at PET3 was good, which has 
not previously been reported, although the numbers assessed were small.  This is reassuring 
as BEACOPP chemotherapy can be associated with diffuse bone marrow uptake, which 
might have made interpretation more challenging.   
The main limitations to our study were that it was not possible for ceCT scans to be re-
reviewed alongside PET-CT scans and we could not measure the impact of PET-CT on 
management.  Bias may have occurred in the scoring of response scans by local readers as it 
was optional to score scans, although readers were evenly split between academic and non-
academic institutions.   
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Conclusion 
Staging of HL patients in this large prospective study confirms that an important proportion 
will be staged differently using PET-CT compared to clinical assessment, CT and bone 
marrow biopsy.  When discordance occurs in the imaging stage, PET-CT is usually more 
accurate than CT, which may impact on management
3,10,14,32
.  These findings support the 
move to a modern standard using PET-CT for staging and suggests that in the vast majority 
of cases ceCT is not required 
6,7
.   
Good agreement between local and expert readers indicates that the 5-PS is robust for 
assessing response when standardised PET protocols are used and it works effectively in the 
community setting and in clinical trials.  The final results of the RATHL trial will determine if 
response adaptation using the 5-PS is successful at improving outcomes in advanced HL.  In 
the meantime, our results strengthen the application of the 5-PS as the optimal method for 
response assessment in HL.   
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Table 1  -level of agreement between RATHL stage (assigned by clinical assessment, ceCT 
and bone marrow biopsy) and the baseline PET-CT. 
 
 RATHL  stage 
PET-CT 1 2 3 4 
1 0 1 2 0 
2 0 406 37 19 
3 0 38 240 15 
4 0 47 74 292 
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Table 2 - Reasons for upstaging and downstaging according to PET-CT compared with the 
RATHL stage. 
 
Upstaging by PET-CT due to N 
(% of upstaged pts) 
Extranodal disease on PET-CT in the following sites: 118 (74.2) 
Bone marrow 92 
Lung 11  
Liver 2  
Pleura 1  
Multiple organs 12  
Nodal disease : 35 (22.0) 
Normal sized nodes that were FDG avid below the diaphragm 20 
Normal sized nodes that were FDG avid above the diaphragm 7  
Splenic FDG avid foci 7  
Both of the above 1  
Difference in opinion : 6 (3.8) 
Imaging findings interpreted differently by the local radiologist  
and the core lab PET CT reader or the treating clinician 
6 
Downstaging by PET-CT due to N (% of downstaged pts) 
Extranodal disease : 25 (33.8) 
Lung 11 
Bone marrow  5 
Pleura 3  
Bone 1  
Adrenal gland 1  
Liver 2 
Small bowel  1  
Multiple organs 1  
Nodal disease : 34 (45.9) 
Enlarged nodes that were not FDG avid below the diaphragm 21 
Enlarged nodes that were not FDG avid above the diaphragm 1 
Splenomegaly on CT, normal FDG uptake 8  
Splenic  lesion/s on ceCT not FDG avid 3  
Splenomegaly on CT & enlarged nodes not FDG avid 1  
Difference in opinion : 15(20.3) 
Imaging findings interpreted differently by the local radiologist and 
the core lab PET CT reader or the local radiologist and the treating 
clinician 
15  
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Table 3 - Agreement between ‘central’ and ‘local’ readers at PET2 using liver threshold (A) 
mediastinal threshold(B) and scores 1-5 (C)  
 
A PET2 (using liver threshold)    B  PET2 (using mediastinal threshold) 
 
 
 
C PET2 (using five scores)   
  Central score 
  1 2 3 4 5 
L
o
c
a
l
 
s
c
o
r
e
 
1 55 59 15 2 0 
2 3 47 20 2 0 
3 3 1 19 5 0 
4 3 5 7 34 2 
5 0 0 0 4 14 
 
 Central  
Local Positive Negative 
Positive 54 15 
Negative 9 222 
 Central 
Local Positive Negative 
Positive 85 12 
Negative 39 164 
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Legends 
Figures  
Figure 1 
Consort flow diagram demonstrating progress of patients through the trial from baseline to 
PET3. 
Figure 2 
CT (left) PET (right) coronal images show a case upstaged by PET-CT.   
Nodal and splenic involvement was reported on CT and interpreted as stage 3.  The PET scan 
showed multifocal uptake in bone marrow upstaging to stage 4. 
Figure 3 
CT (left) PET (right) axial images show a case downstaged by PET-CT.   
There was nodal disease in the mediastinum and a 22mm lung nodule in the left lung 
(arrowed), reported on CT as stage 4. The PET scan showed high uptake in lymph nodes but 
no FDG uptake in the lung nodule suggesting the nodule was unlikely to be due to 
lymphoma interpreted as stage 2 (Panel A).  After treatment, there was resolution of uptake 
in lymph nodes but the lung nodule (arrowed) was unchanged (Panel B). 
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Figure 1 Registered 
N =1214 
Baseline PET 
Available 
N =1171 
Core labs *: 
UK  n=926 
Italy  n=128 
AUS/NZ  n=82 
Sweden n=24 
Denmark n=11 
 
 
Not assessable 
N = 40 
Baseline scans could  n = 27 
not be retrieved   
IV contrast used in CT 
component of PET-CT n = 13 
 
 
PET 2 
N = 1123 
PET 3  
N = 161 
 
   
 
   
PET scan not 
assessable due to 
scanning protocol 
violations 
N = 67 
 
‘Central’ and ‘local’ 
scores available 
N=300 
UK  n=163 
Italy  n=98 
AUS/NZ  n=39 
 
No PET 3 scan 
performed 
N=1050 
 
*UK Core Lab read scans from UK & Norway 
Australia Core Lab read scans from Australia and New Zealand 
No PET2 scan 
performed 
N = 21 
 
Central score given, 
Local readers chose 
not to score scans 
N = 600 
 
Performed at one of 
the Core Labs 
N = 223 
 
‘Central’ and ‘local’ 
scores available 
N= 47 
UK  n=29 
Italy  n=18 
 
Central score given, 
Local readers chose 
not to score scans 
N = 88 
 
Performed at one of 
the Core Labs 
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Excluded  
Misdiagnosis, not HL, n = 3 
Eligible for analysis 
N =1211 
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